MAGNETOM Skyra Fit

The MAGNETOM Skyra Fit is a 3 Tesla magnetic resonance diagnostic device intended to produce high-resolution anatomical, functional, and spectroscopic data to aid physicians in diagnosis and guide interventional procedures. It achieves this through an upgraded hardware platform and the syngo MR XA50A software, which introduces advanced imaging capabilities such as TSE MoCo for motion correction and automatic fiducial detection for enhanced MR Breast Biopsy.

The MAGNETOM Skyra Fit is a 3 Tesla magnetic resonance diagnostic device (MRDD) designed for generating a comprehensive range of images, including transverse, sagittal, coronal, and oblique cross-sections, as well as spectroscopic images and spectra. Its primary purpose is to display the internal structure and/or function of the head, body, or extremities, providing information that, when interpreted by a trained physician, can assist in diagnosis; the system also supports the use of contrast agents and can be utilized for imaging during interventional procedures with MR-compatible devices. This system, operating with the new syngo MR XA50A software, represents an upgrade from the MAGNETOM Verio and includes modified hardware such as the cover and Electronic Power Cabinet (EPC). Key software enhancements introduce new features like TSE MoCo for image-based motion correction in TSE pulse sequences and automatic fiducial detection to improve MR Breast Biopsy procedures, alongside modified features like Fast GRE RefScan for speed-optimized reference scans in echo planar imaging. Comprehensive nonclinical performance testing, including image quality assessments using sample clinical images, hardware bench tests, and software verification and validation, confirmed the device performs as intended across its new and modified features.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the TSE MoCo feature quantitatively compare to previous motion correction algorithms or acquisitions without motion correction in terms of image artifact reduction and diagnostic clarity across different anatomical regions?; What is the measured impact of the automatic fiducial detection feature on overall MR Breast Biopsy procedure time and targeting accuracy compared to manual fiducial identification methods?; Are there specific imaging protocols or patient demographics where the Fast GRE RefScan provides the most substantial improvements in scan efficiency without compromising diagnostic image quality or quantitative accuracy?; Beyond the listed hardware modifications (cover, EPC), what are the specific performance implications, such as changes in signal-to-noise ratio, gradient fidelity, or radiofrequency transmission efficiency, resulting from upgrading a MAGNETOM Verio to the MAGNETOM Skyra Fit architecture?; What is the validated range of compatibility of the MAGNETOM Skyra Fit with various third-party MR-compatible interventional devices, and does the syngo MR XA50A software offer specific tools or workflows to streamline these advanced procedures beyond MR Breast Biopsy?